# YZY Biopharma Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yzy-biopharma-co

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.yzybio.com
- Total disclosed funding: $31M
- Latest round: Series B (Sep 10, 2021)
- Investors on record: 7

## About

Established in 2010 and based in Wuhan, China, YZY Biopharma Co., Ltd is a biotechnology medicine developer that focuses on the development of bispecific antibody drugs. Pengfei Zhou, the founder and president of the company, worked at Schering-Plough, Sino-American Crown Bio, Pfizer-Crown Asia Cancer Research Center, etc. The company has a 4,000 square meter R&D building and an 800 square meter antibody pilot production workshop and applied for 83 core technology patents, including 14 PCT international patents, and received 32 invention patent authorizations. In July 2022, YZY Biopharma Co., Ltd raised CNY 200 million in pre-series C funding. In September 2023, it was listed on the Hong Kong Stock Exchange.

The company engages in the development of bispecific antibody drugs. Its main products include bispecific antibody products such as M802—HER2×CD3, M701—EPCAM×CD3 and Y150. The company's products are used in diseases such as tumors, immunity, inflammation, cardiovascular and infections.



The company's net income for 2022 was CNY -188.86 million.

## Funding rounds

- Series B, Sep 10, 2021 — Qianshan Capital, Camel Equity Investment
- Series B, Dec 2, 2020, $31M — TD Capital Ventures, Sanhhua Hongdao Capital, BGI Co-WIN Investment Management
- Series A, May 9, 2016 — Panlin Capital, Shenogen Pharma Group

## Investors

- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A
- Shenogen Pharma Group — Series A
- TD Capital Ventures (https://capitalatlas.ai/funds/td-capital-ventures) — Series B
- Sanhhua Hongdao Capital (https://capitalatlas.ai/funds/sanhhua-hongdao-capital) — Series B
- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Series B
- Qianshan Capital — Series B
- Camel Equity Investment (https://capitalatlas.ai/funds/camel-equity-investment) — Series B